US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
accepted:
23
09
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG). The ELEVATE study aimed to examine clinical-practice outcome data on eculizumab effectiveness in US adults with MG (generalized or ocular). This paper reports the findings on MG exacerbations and crises and associated healthcare resource utilization, and the use of rescue therapy. A retrospective chart review was conducted of US adults with MG who initiated eculizumab. Outcomes assessed for up to 2 years before and after eculizumab initiation included percentages and rates per patient per year (PPPY) of exacerbations and crises (the latter defined as intubation/impending intubation), healthcare resource utilization, and rescue therapy administration. A total of 119 patients diagnosed with MG were enrolled in the study; 92 patients had ≥ 3 months of data both before and during eculizumab therapy and were included in the analyses. The mean rate of MG exacerbations decreased from 0.385 PPPY before eculizumab initiation to 0.152 PPPY during eculizumab treatment (p = 0.0034); the mean rate of MG crises decreased from 0.411 to 0.056 PPPY (p = 0.0018). Rates of healthcare resource utilization and rescue therapy use also decreased significantly during eculizumab treatment. This retrospective chart review analysis provides evidence for a beneficial impact of eculizumab treatment on the incidence of MG exacerbations and crises and associated healthcare resource utilization in clinical practice, and on rescue therapy use. These data further support the therapeutic benefits of eculizumab in patients with MG.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG). The ELEVATE study aimed to examine clinical-practice outcome data on eculizumab effectiveness in US adults with MG (generalized or ocular). This paper reports the findings on MG exacerbations and crises and associated healthcare resource utilization, and the use of rescue therapy.
METHODS
METHODS
A retrospective chart review was conducted of US adults with MG who initiated eculizumab. Outcomes assessed for up to 2 years before and after eculizumab initiation included percentages and rates per patient per year (PPPY) of exacerbations and crises (the latter defined as intubation/impending intubation), healthcare resource utilization, and rescue therapy administration.
RESULTS
RESULTS
A total of 119 patients diagnosed with MG were enrolled in the study; 92 patients had ≥ 3 months of data both before and during eculizumab therapy and were included in the analyses. The mean rate of MG exacerbations decreased from 0.385 PPPY before eculizumab initiation to 0.152 PPPY during eculizumab treatment (p = 0.0034); the mean rate of MG crises decreased from 0.411 to 0.056 PPPY (p = 0.0018). Rates of healthcare resource utilization and rescue therapy use also decreased significantly during eculizumab treatment.
CONCLUSIONS
CONCLUSIONS
This retrospective chart review analysis provides evidence for a beneficial impact of eculizumab treatment on the incidence of MG exacerbations and crises and associated healthcare resource utilization in clinical practice, and on rescue therapy use. These data further support the therapeutic benefits of eculizumab in patients with MG.
Identifiants
pubmed: 39470958
doi: 10.1007/s40801-024-00457-8
pii: 10.1007/s40801-024-00457-8
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242. https://doi.org/10.1177/1756286419832242 .
doi: 10.1177/1756286419832242
pubmed: 30854027
pmcid: 6399761
Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167–78. https://doi.org/10.1097/CND.0000000000000034 .
doi: 10.1097/CND.0000000000000034
pubmed: 24872217
Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16–22. https://doi.org/10.1177/1941875210382918 .
doi: 10.1177/1941875210382918
pubmed: 23983833
pmcid: 3726100
Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. 2018;58(1):99–105. https://doi.org/10.1002/mus.26114 .
doi: 10.1002/mus.26114
Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693–9. https://doi.org/10.1002/mus.26689 .
doi: 10.1002/mus.26689
pubmed: 31469909
Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48(5):1253–60. https://doi.org/10.1212/wnl.48.5.1253 .
doi: 10.1212/wnl.48.5.1253
pubmed: 9153452
Desai R, Abbas SA, Fong HK, Lodhi MU, Doshi R, Savani S, et al. Burden and impact of takotsubo syndrome in myasthenic crisis: a national inpatient perspective on the under-recognized but potentially fatal association. Int J Cardiol. 2020;299:63–6. https://doi.org/10.1016/j.ijcard.2019.09.054 .
doi: 10.1016/j.ijcard.2019.09.054
pubmed: 31611084
Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13(2):85–94. https://doi.org/10.1097/CND.0b013e31822c34dd .
doi: 10.1097/CND.0b013e31822c34dd
pubmed: 22361692
pmcid: 3291869
Phillips G, Abreu C, Goyal A, Li Y, Whangbo A, Gelinas D, et al. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2021;12: 809999. https://doi.org/10.3389/fneur.2021.809999 .
doi: 10.3389/fneur.2021.809999
pubmed: 35115997
Habib AA, Sacks N, Cool C, Durgapal S, Dennen S, Everson K, et al. Hospitalizations and mortality from myasthenia gravis: trends from 2 US national datasets. Neurology. 2024;102(2): e207863. https://doi.org/10.1212/wnl.0000000000207863 .
doi: 10.1212/wnl.0000000000207863
pubmed: 38165317
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86. https://doi.org/10.1016/s1474-4422(17)30369-1 .
doi: 10.1016/s1474-4422(17)30369-1
pubmed: 29066163
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14–24. https://doi.org/10.1002/mus.26447 .
doi: 10.1002/mus.26447
pubmed: 30767274
pmcid: 6619057
Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, et al. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. J Neurol. 2024;271(9):6114–26. https://doi.org/10.1007/s00415-024-12569-w .
doi: 10.1007/s00415-024-12569-w
pubmed: 39052039
pmcid: 11377470
Abuzinadah AR, Alanazy MH, Butt NS, Barohn RJ, Dimachkie MM. Exacerbation rate in generalized myasthenia gravis and its predictors. Eur Neurol. 2021;84(1):43–8. https://doi.org/10.1159/000512077 .
doi: 10.1159/000512077
pubmed: 33321491
Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1: EVIDoa2100066. https://doi.org/10.1056/EVIDoa2100066 .
doi: 10.1056/EVIDoa2100066
pubmed: 38319212
Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024;271(9):6209–19. https://doi.org/10.1007/s00415-024-12588-7 .
doi: 10.1007/s00415-024-12588-7
pubmed: 39080054
pmcid: 11377599
Katyal N, Narula N, Govindarajan R. Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neuromuscul Dis. 2021;8(2):287–94. https://doi.org/10.3233/JND-200584 .
doi: 10.3233/JND-200584
pubmed: 33325394
pmcid: 8075396
Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochmuller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020;38(7):715–28. https://doi.org/10.1007/s40273-020-00912-8 .
doi: 10.1007/s40273-020-00912-8
pubmed: 32363541
Liu C, Li T, Wang Q, Xu A, Wu B. Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychol Health Med. 2021;26(2):221–7. https://doi.org/10.1080/13548506.2020.1807577 .
doi: 10.1080/13548506.2020.1807577
pubmed: 32877257
Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1103–25. https://doi.org/10.1007/s40120-021-00285-w .
doi: 10.1007/s40120-021-00285-w
pubmed: 34687427
pmcid: 8540870
Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, et al. Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology. 2020;94(3):e299–313. https://doi.org/10.1212/WNL.0000000000008688 .
doi: 10.1212/WNL.0000000000008688
pubmed: 31801833
Souayah N, Nasar A, Suri MF, Kirmani JF, Ezzeddine MA, Qureshi AI. Trends in outcomes and hospitalization charges among mechanically ventilated patients with myasthenia gravis in the United States. Int J Biomed Sci. 2009;5(3):209–14.
doi: 10.59566/IJBS.2009.5209
pubmed: 23675139
pmcid: 3614787
Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol. 1982;39(6):350–4. https://doi.org/10.1001/archneur.1982.00510180028007 .
doi: 10.1001/archneur.1982.00510180028007
pubmed: 7092611
Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817–27. https://doi.org/10.1016/s0272-6386(12)80135-1 .
doi: 10.1016/s0272-6386(12)80135-1
pubmed: 8203364
Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102(3):177–93. https://doi.org/10.1016/j.pharmthera.2004.04.002 .
doi: 10.1016/j.pharmthera.2004.04.002
pubmed: 15246245
Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299. https://doi.org/10.3389/fimmu.2018.01299 .
doi: 10.3389/fimmu.2018.01299
pubmed: 29951056
pmcid: 6008653
Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023;270(8):3862–75. https://doi.org/10.1007/s00415-023-11699-x .
doi: 10.1007/s00415-023-11699-x
pubmed: 37103755
pmcid: 10134722
Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, et al. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol. 2023;118(4):419–31. https://doi.org/10.1007/s12185-023-03630-x .
doi: 10.1007/s12185-023-03630-x
pubmed: 37515657
Greene E, Cutter G, Muppidi S, Juel V, Rodrigues E, Korideck H, et al. Myasthenia gravis activities of daily living (MG-ADL) response to eculizumab treatment in patients from the generalized myasthenia gravis registry (P1–5.020). Neurology. 2023;100(17 Suppl. 2):2071. https://doi.org/10.1212/wnl.0000000000202295 .
doi: 10.1212/wnl.0000000000202295
Pulley M, Macwan S, Nowak R, Mozaffar T, Rodrigues E, Korideck H, et al. Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: a retrospective analysis of registry data (P1-5.002). Neurology. 2023;100(17 Suppl. 2):2183. https://doi.org/10.1212/wnl.0000000000202372 .
doi: 10.1212/wnl.0000000000202372